Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma reported Q1 FY26 (quarter ended June 30, 2025) results. On a standalone basis, revenue from operations rose to ₹2,541.36 crores (vs ₹2,412.62 cr in Q1 FY25), while profit after tax declined to ₹412.76 crores (vs ₹476.42 cr) with basic EPS of ₹10.00. On a consolidated basis, revenue grew ~24.5% YoY to ₹3,570.35 crores, but PAT fell to ₹444.62 crores (vs ₹543.07 cr) and EPS dropped to ₹10.62, largely because finance costs and depreciation jumped following the October 2024 acquisition of Bharat Serums and Vaccines (BSV) for ₹13,768 crores. The board declared an interim dividend of ₹1 per share (100% on face value), approved the acquisition of BSV's Branded Generic Women Health Rx Portfolio via slump sale, and authorised raising up to ₹1,000 crores through commercial papers. The auditor's report carries an Emphasis of Matter on the ongoing income tax search proceedings, where disallowances of ~₹1,534 cr (u/s 37(1)) plus additional claims have been raised and appealed. Dr. Sanjay Koul, Chief Marketing Officer, resigned effective August 1, 2025.
For shareholders: the 100% interim dividend (₹1/share) provides near-term cash return, and the BSV Women Health portfolio acquisition extends the company's specialty play, but profitability is under pressure from higher finance and amortisation costs post the large BSV deal. The consolidated PAT decline of ~18% YoY and the sizeable income-tax disallowance appeal (~₹1,825+ cr) are the key risks to watch; both could weigh on stock sentiment in the near term.